Format

Send to

Choose Destination
Contemp Clin Trials. 2011 May;32(3):437-45. doi: 10.1016/j.cct.2011.01.008. Epub 2011 Jan 23.

Effect of statin therapy on disease progression in pediatric ADPKD: design and baseline characteristics of participants.

Author information

1
Department of Medicine, University of Colorado Denver, Aurora, CO, USA. Melissa.Cadnapaphornchai@ucdenver.edu

Abstract

Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic kidney condition and is associated with important renal and cardiovascular manifestations in childhood. Renal cystic disease can be documented in some cases as early as in utero. Early intervention is critical if the long-term complications of this condition, including end-stage renal disease, are to be ameliorated. Here we describe our ongoing randomized double-blind placebo-controlled phase III clinical trial to assess the effect of pravastatin treatment on renal and cardiovascular disease progression in 107 children and young adults age 8-22 years with ADPKD who are receiving the angiotensin converting enzyme inhibitor lisinopril. Baseline demographic and laboratory data are provided. Results of this study could markedly impact the standard of care for evaluation and treatment of ADPKD in this population.

PMID:
21266204
PMCID:
PMC3077046
DOI:
10.1016/j.cct.2011.01.008
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center